peripherally ("immune CRH") and participates directly in the inflammatory reaction as a potent degranulator of mast cells, mediating stress-triggered states such as asthma and migraine headaches. He demonstrated sexual dimorphism in the CRH and stress system response, with female predominance, and developed a clinically useful CRH test employed in the differential diagnosis of Cushing syndrome and pseudo-Cushing states and adrenal insufficiency. He employed this test as a research tool in the study of complex human disorders. He delineated the key pathophysiology of a number of human states characterized by high or low CRH secretion, such as, respectively, melancholic depression, anorexia nervosa, idiopathic insomnia, and obligate athleticism or atypical and seasonal depression, postpartum blues/depression, and the chronic fatigue and fibromyalgia syndromes. He extended this work to other common human states, such as obesity/ metabolic syndrome, sleep disorders, autoimmune diseases, and posttraumatic stress disorder. He synthesized seemingly disparate mechanisms and disorders into a logical heuristic model that has been accepted and referred to by thousands of investigators. His work has influenced many fields of medicine beyond endocrinology and metabolism, including internal medicine and pediatrics, rheumatology/immunology, psychology and psychiatry, sleep medicine, reproductive medicine, surgery, epidemiology, and basic and translational sciences.
The above work has been fully replicated, has accumulated more than 70 000 citations, has resulted in a Hirsch index of more than 130 and, most importantly, has been transformative and followed by significant work by other investigators. A series of prestigious awards and accolades has accompanied this work, including 2 laureate awards of the Endocrine Society and the 2011 John Kluge Distinguished Chair in Technology and Society of the Library of Congress. He was honored with the 2011 Aristeion Bodossaki Award, the highest distinction for accomplishment in the Sciences in Greece. Recently, Dr Chrousos received the 2012 Albert Struyvenberg Medal of the European Society of Clinical Investigation "for excellence and leadership in translational and multidisciplinary biomedical research." In 2014 he received the inaugural George Papanicolaou Award of the University of Athens. He is included in the list of the 400 most cited influential scientists in the world over the last 15 years.
Dr Chrousos was inducted as a Master of both the American College of Endocrinology and the American College of Physicians and a Fellow of the Royal College of Physicians, United Kingdom. He served as the president of the European Society of Clinical Investigation. He is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, The Institute of Medicine of the National Academy of Sciences, and the Academia Europaea.
At the NIH, Dr Chrousos runs one of the best endocrine training programs in the world and has fostered the careers of more than 60 distinguished, award-winning, world-class physician-scientists and scientists. After a 25-year distinguished career in the Intramural Program of the NIH, Dr Chrousos returned to his country and has assumed leadership roles at the University of Athens and in European and international medicine and academia. Dr Chrousos has published extensively and is recognized worldwide. Most importantly, his publications are seminal.
Jan-Ake Gustafsson, MD, PhD
Citation for the 2014 Ernst Oppenheimer Award of the Endocrine Society to Dr W. Lee Kraus Dr W. Lee Kraus has made tremendous contributions to our understanding of the mechanisms by which nuclear receptors and factors that control NAD + metabolism function as regulators of gene transcription. His remarkably insightful discoveries at the forefront of research on chromatin, transcription regulation, and nuclear signaling pathways have fundamentally changed our understanding of how signalregulated transcription factors, coregulator complexes, and histone-and chromatin-modifying enzymes collaborate to modulate chromatin structure and gene expression. His work has provided paradigm-shifting insights into fundamental aspects of a variety of biological systems, from reproduction and metabolism to cancer and inflammation.
Dr Kraus is currently the director of the Cecil H. and Ida Green Center for Reproductive Biology Sciences at the University of Texas Southwestern Medical Center and is also Professor and Vice Chair for Basic Sciences in the Department of Obstetrics and Gynecology and Professor in the Department of Pharmacology. He also holds the Cecil H. and Ida Green Distinguished Chair in Reproductive Biology Sciences. Prior to joining the faculty at UT Southwestern, Dr Kraus was a professor in the Department of Molecular Biology and Genetics at Cornell University in Ithaca and held a joint appointment in the Department of Pharmacology at the Weill Medical College of Cornell University in New York City.
Dr Kraus was the first to develop an in vitro chromatin assembly and transcription system that precisely and faithfully recapitulates the known physiological specificity of transcription regulation by steroid hormones acting through their cognate nuclear receptors. With this work, he moved nuclear receptor-regulated transcription into a defined molecular system where it could, for the first time, be studied using powerful biochemical analyses. His work showed that chromatin, rather than being an inert substrate for transcription, actually plays an important role in determining ligand-dependent transcriptional responses, coactivator function, and nonclassical estrogen receptor signaling.
Dr Kraus' laboratory has also elucidated novel connections between nuclear NAD + synthesis and gene regulation mediated by poly(ADP-ribose) polymerase-1 (PARP-1), an abundant and ubiquitous chromatin-associated protein. This work uncovered critical roles for PARP-1 in influencing chromatin structure and gene expression. Using a range of biophysical, biochemical, and molecular approaches, he found that PARP-1 plays key roles in the modulation of chromatin structure and gene expression in response to extracellular signals, such as estrogens and TNFα. This convergence of signaling pathways represents a new area that has had a broad impact on our understanding of signaling networks in endocrine-responsive cells.
In his most recent work, Dr Kraus has developed novel computational tools to integrate and analyze data from a wide variety of genomic approaches to study the immediate and direct effects of estrogen and TNFα on the transcriptomes of hormone-dependent breast cancers and other signalresponsive biological systems. These studies, which have significantly altered our view of signal-regulated transcriptional responses, have characterized the robust and rapid changes that occur across the genome in response to stimuli, including assembly of functional enhancers at transcription factor binding sites and the expression of thousands of previously unannotated noncoding RNA transcripts of unknown function.
Dr Kraus' approaches reflect not only his broad interests and expertise in molecular and cellular biology but also his wider interests in physiology and disease. He has already trained an impressive number of doctoral students and postdoctoral associates, and he is an extremely popular mentor. Not surprisingly, his laboratory is very highly regarded both nationally and internationally. Dr Kraus has been extremely generous in providing expertise and critical reagents to many researchers throughout the world who have been interested in adopting the novel methodologies that he has developed and refined to study gene regulation.
Dr Kraus has also contributed much in service as a member of the editorial boards of several excellent journals and is currently serving as an editor for Molecular Endocrinology and Molecular Cancer Research. He was a co-organizer of the 2008 Keystone Symposium on the Nuclear Receptor Superfamily, the lead organizer for the 2010 Keystone Symposium on Nuclear Receptors: Signaling, Gene Expression, and Cancer, and the founding organizer of the Cold Spring Harbor Laboratory Meeting on the PARP family. He has also served as a member of the Annual Meeting Steering Committee of the Endocrine Society and recently completed a term on the Molecular and Cellular Endocrinology NIH Study Section.
Lee Kraus' exceptional contributions to endocrinology have had a major impact on the field and make him a highly deserving recipient of the 2014 Ernst Oppenheimer Award of the Endocrine Society.
Benita Katzenellenbogen, MD DeGroot's research has focused on thyroidology and has touched almost every aspect of the discipline. With John Stanbury and colleagues in the Thyroid Unit at the Massachusetts General Hospital, he pioneered studies of thyroid hormone synthesis and iodine metabolism. With Sam Refetoff and colleagues at the University of Chicago, he investigated genetic thyroid disorders including recognition of thyroid hormone resistance syndrome, cloning of hTRα, and studies of molecular mechanisms of thyroid hormone action. At Chicago, he initiated decades of research on thyroid cancer, including classic studies of the natural history of thyroid cancer (cited more than 700 times), studies that linked radiation exposure and thyroid cancer risk, and gene therapy approaches for thyroid cancer in animal models. His laboratory also examined autoimmune thyroid disease (AITD), including recognition of the CTLA-4 gene in predisposition to AITD, the identification of TPO as a key antigen for autoimmune antibodies, as well as T-cell epitope mapping of TPO and the TSH receptor. As one might expect for someone with more than 450 publications, this breadth of research involved the mentoring of generations of young scientists from around the world. Indeed, a hallmark of DeGroot's work has been international collaborations that have reached every continent.
Arguably, his most enduring impact has involved innovative texts and other educational media. DeGroot has always been at the forefront of this field. DeGroot wrote an authoritative text, The Thyroid and Its Diseases, which included an international editor group. He later created Endocrinology, a comprehensive 3-volume text, again with an international group of editors. It has become the standard in the field and is starting its seventh edition. DeGroot has been the driving force behind two online endocrine texts-www. thyroidmanager.org and www.endotext.org. His goal was to ensure that updated information was available worldwide and free.
DeGroot has held leadership roles throughout his career. As Section Chief at the University of Chicago, he attracted first-rate talent to create one of the best divisions in the country. A few members-Don Steiner, Arthur Rubenstein, Sam Refetoff, Ken Polonsky, Graeme Bell, Eve Van Cauter, Roy Weiss, Murray Favus, and Robert Rosenfield-exemplify the caliber and impact of this group, each of whom hosted trainees from around the world. DeGroot has been consistently involved in the American Thyroid Association and European Thyroid Association and is perhaps the most widely known leader the thyroid field. Leslie and his elegant wife, Helen, have served as ambassadors of academic endocrinology throughout the world, enlivening social events, and welcoming new trainees and faculty on sabbaticals. The tenure of DeGroot's leadership is underscored by the fact that he served as President of the American Thyroid Association in 1973 and remains an active member. In the Endocrine Society, he has been actively engaged throughout his career, serving on numerous committees, the Council, and editorial boards. Leslie provided a 90-minute interview in the Endocrine Society's program to capture the history of the field-it is a fascinating reflection on the field and his role.
DeGroot Dr Accili's beginnings in research can be traced to the pioneering work of Roth, Gorden, Kahn, LeRoith, and Taylor, in their quest to understand how insulin works and to establish structure-function relationships in the insulin receptor using naturally occurring mutations in patients with genetic syndromes of insulin resistance. This led him to an easy transition to the then-burgeoning field of gene knockouts, which he used to extend our knowledge of the insulin signaling pathway. Beginning in the mid-90s, Dr Accili became interested in testing the hypothesis that the forkhead transcription factor Foxo was the long-sought mediator of insulin action on gene expression. This research has led him into surprising and exciting new areas that have furthered our understanding of diabetes pathogenesis, integrated physiology of insulin action, and mechanisms of pancreatic β-cell failure. He is best known for studies defining mechanisms of hepatic insulin action, including glucose production, lipid synthesis, and regulation of bile acid pool composition. He has made significant contributions to the area of insulin resistance and cardiovascular disease, one of the main unmet therapeutic needs in the treatment of diabetes. His work has led to the identification of mechanisms in endothelial cells and liver that explain the intricate relationship between glucose control, insulin sensitivity, and macrovascular atherosclerotic disease. Perhaps his most important contributions to date have been in the area of pancreatic β-cell biology, specifically in the demonstration that β-cell failure, long held to be the consequence of apoptotic cell death, does in fact result from a dedifferentiation process, whereby β cells lose the ability to make insulin, revert to an earlier progenitor stage, and occasionally convert to other hormone-producing cells. Germane to this discovery is the observation that enteroendocrine cells have the potential to give rise to fully functional insulin-producing cells in the gut-a property that is currently being further investigated as a therapeutic opportunity for type 1 diabetes. Dr Accili has received numerous awards, including the American Diabetes Association's Lilly Award, the University of Chicago's Steiner Award, and the Claude Bernard Medal of the European Association for the Study of Diabetes. His work has been published in leading medical journals. A member of several editorial boards, he also serves on numerous advisory panels for academia, government, and industry. He is an elected member of the Association of American Physicians and the American Society for Clinical Investigation. His work is supported by the NIH, the American Diabetes Association, the Russell Berrie Foundation, the Brehm Coalition, and the JPB Foundation.
Jesse Roth, MD
Citation for the 2014 Clinical Investigator Award of the Endocrine Society to Dr James Fagin
Dr James Fagin, Chief of Endocrinology at Memorial Sloan Kettering Cancer Center in New York, is internationally recognized for seminal contributions to understanding of thyroid cancer pathogenesis, identification of key therapeutic targets of the disease, and developing mechanism-based therapies for patients with metastatic thyroid cancer. This recently culminated in a remarkable clinical trial, in which patients with tumors that no longer responded to radioiodine were pretreated with a selective MEK inhibitor, leading to restoration of radioiodine uptake and responsiveness to radioiodine therapy. This groundbreaking study is the culmination of a veritable tour de force, which followed from a beautiful series of preclinical studies in cells and in mouse models that faithfully recapitulated the human disease phenotype. He was the first to establish that benign and malignant thyroid tumors, including many of the tumors arising within multinodular goiters, were clonal. He had a leading role in establishing mechanisms of RET recombination in post-Chernobyl pediatric thyroid cancers. He was the first to describe nonoverlapping mutations of RET, RAS, and BRAF in papillary thyroid cancer, all of which constitutively activate MAPK signaling, thus providing compelling genetic evidence for involvement of this pathway in thyroid cancer pathogenesis. He buttressed these observations with functional studies in cell lines and by developing mouse transgenic and knock-in models of thyroid cancer that faithfully recapitulate the human disease. His work provided the conceptual framework that underlies many of the promising experimental new therapies for thyroid cancer using small molecule kinase inhibitors. He hypothesized and subsequently validated that refractoriness to radioiodine therapy could be overcome in patients with metastatic thyroid cancer. He created thyroid cell lines with conditional expression of tyrosine-substituted RET mutants and showed that down-regulation of these thyroidspecific genes was prevented by tyrosine substitution at RET--Y1062, a site that allows RET kinase to couple to Shc and activate RAS-MAPK signaling. He went on to show that conditional expression of mutant RAS or MAPKK also inhibited Tg, TPO, and the sodium iodine symporter and that this could be prevented by treatment with MEK inhibitors. After his discovery of BRAF mutations in the disease, he showed that conditional expression of this oncoprotein recapitulated these findings. He then went on to make mouse models of Braf-induced thyroid cancer that showed high penetrance of the disease and profound down-regulation of thyroid-specific gene expression and thyroid hormone biosynthesis. He used a conditionally expressed BRAF allele to show that dedifferentiation and impairment in iodide transport could be reversed by genetic or pharmacological blockade of BRAF-MAPK signaling, confirming the experiments performed in vitro almost a decade earlier.
He next went on to test the clinical viability of this approach in a trial of patients with radioiodine refractory metastatic thyroid cancer. Patients underwent 124 I PET scans after stimulation with recombinant TSH before and again after receiving a 4-week course of selumetinib. Twelve of 20 patients had marked increased uptake on the 124 I-PET scans after treatment with the drug. Eight of these patients, including all 5 with an NRAS gene mutation, had lesional uptakes that by dosimetry predicted that an effective dose (ED) of 2000 cGy of 131 I could be delivered, and they were therefore treated with a therapeutic dose of 131 I. In these patients, metastatic tumors decreased in size, and thyroglobulin levels, which serve as an effective biomarker for the disease, dropped remarkably. A phase 3 randomized placebo-controlled international multicenter trial (ASTRA), will now test whether pretreatment with selumetinib increases remission rates after adjuvant postoperative radioiodine treatment of patients presenting with locally advanced forms of thyroid cancer.
Patients with BRAF mutations appeared to benefit the least from this approach. Dr Fagin's laboratory went on to show that in thyroid cancer cells, rebound in ERK signaling is accompanied by a marked activation of HER3 signaling, caused by induction of HER3 and by concomitant autocrine secretion of neuregulin-1. The HER family kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to growth inhibition by RAF or MEK inhibitors. This provides a rationale for combining inhibitors of ERK signaling with inhibitors of feedback-reactivated HER signaling, an approach that has spawned new clinical trials.
He has been Chair of the National Institute of Health Endocrinology Study Section, Editor of Endocrinology and Clinical Endocrinology, and Editor-in-Chief of EndocrineRelated Cancer. He has been honored by the European Thyroid Association, the American Thyroid Association, and the UK Society of Endocrinology.
The Endocrine Society accords this exemplary clinicianscientist the recognition of the Clinical Investigator Award.
Shlomo Melmed, MD At UCLA, Dr Tontonoz continued to develop his interest in nuclear receptors as key transcriptional regulators of metabolic pathways. His was among the first groups to outline an important role for the nuclear receptor liver X receptor (LXR) in the reverse cholesterol transport pathway. His discovery in 2002 that synthetic LXR ligands inhibited the development of atherosclerosis catalyzed interest in the LXR pathway as a potential target for cardiovascular therapeutics.
Over the years, the Tontonoz laboratory has identified a cadre of transcriptional targets of LXR signaling and has elucidated their physiological functions in metabolic homeostasis. Recently, his group identified the E3 ubiquitin ligase IDOL and demonstrated that it targets the LDL receptor for degradation and in doing so opposes sterol regulatory element-binding protein (SREBP) action in cells. The discovery of the LXR-IDOL-LDLR pathway has implications for the development of a new class of lipid-modifying drugs. Dr Tontonoz has also outlined complex relationships between LXR-dependent lipid metabolism and the pathogenesis of the metabolic syndrome. He showed that LXRs play critical roles in the control of liver and adipose tissue lipogenesis in the setting of obesity and insulin resistance. Dr Tontonoz's study of the role of LXR in sterol homeostasis has led to the elucidation of previously unrecognized connections between lipid metabolism, inflammatory signaling, and immunity. In 2003, his group was the first to identify LXRs as potent inhibitors of inflammation. He went on to show that LXR-dependent gene expression was important for immunity to intracellular pathogens and that loss of LXR signaling leads to aberrant immune system activation and the development of autoimmune disease. Finally, he showed that the ability of LXR to control cellular cholesterol levels was a gating factor in the proliferation and function of T cells.
Stemming from his work as a graduate student, Dr Tontonoz has also continued to pursue his interest in adipocyte biology. Using high-throughput screening approaches, he has identified small molecules and genes involved in the regulation of adipocyte differentiation. Most recently, his group has characterized the coregulator TLE3 as a white-adipocyte selective transcriptional regulator that works with PPARγ and PRDM16 to specify adipocyte-subtype selective gene expression.
Dr Tontonoz is particularly proud of his record as a mentor for young academic investigators. Trainees from his laboratory now run independent research groups around the world, at institutions (1975) (1976) (1977) (1978) (1979) (1980) . Dr Rayfield's research on animal models of virus-induced diabetes received international recognition and resulted in his being elected to the American Society of Clinical Investigation (1982) . He is a Fellow in the American College of Physicians. Dr Rayfield has willingly and voluntarily provided his time to a variety of extramural agencies that have included service as an ad hoc member of NIH Study Sections, Task Forces, and Contract Reviews. In his clinical research in diabetes and general endocrinology, he has mentored and collaborated with many medical students and fellows who have subsequently become established clinical investigators throughout the world. He has published 70 peer-reviewed articles, 33 chapters for textbooks and a book on diabetes for laymen. He was President of the American Diabetes Association, New York Downstate Affiliate (1993) (1994) , and received a Professional Education Service Award Although Dr Rayfield has served the Society importantly through his service on several committees, his greatest achievements have been in the areas of development and fundraising where he has innovatively set a new standard of civic responsibility. In large part through his efforts, the Society is more than two thirds of the way to its million dollar goal for the Library. The Sawin Library will be an enduring legacy to future endocrinologists and scholars, and much of the credit for its creation must belong to Dr Rayfield. In the future, we can envision the Resource Center of the Library sponsoring development of materials and conferences related to the goals of our Society in both endocrine research and clinical practice. It is for these significant contributions to our Society that he has been recognized by the Endocrine Society with the 2014 Sidney H. Ingbar Distinguished Service Award.
Leonard Wartofsky, MD, MACP David's accomplishments have focused on elucidating the genetic architecture of type 2 diabetes, a complex genetic disorder that has previously defied genetic approaches to define its underlying genetic structure. Despite its known high heritability index, type 2 diabetes has proven relatively resistant to traditional approaches. Dr Altshuler approached this daunting problem by first serving as the principal architect of the HapMap Project wherein he and his colleagues first elucidated the complex haplotype structure of the human genome once its full sequence became available. They first had to envision and then build the correct statistical and bioinformatic tools required for such investigations as few existed when they started their quest. Once this impressive task was accomplished, they promptly made all of these tools available to all investigators internationally for their own use. He then demonstrated their utility in analyzing genome-wide association studies (GWAS) to begin to dissect the genetic architecture of several complex traits of several common diseases that collectively account for so much of our health care expenditures. Initially, David and his colleagues were unable to find many genes in type 2 diabetes using these approaches, but whereas a lesser individual might have given up, they persisted.
He and his team have now convincingly proven that, whereas previous association studies failed to identify replicable genes that are risk factors for this disorder, much of these failures could be explained by the lack of study populations of sufficient size and homogeneity. Ultimately, they demonstrated that whereas only a few genes could be identified by the study of a few thousand patients with diabetes and controls, when these disease populations were expanded to~50 000 patients and an equal number of controls, a clear and reproducible panel of >70 genes could be clearly discerned using the important analytic building blocks they had built. Executing the logistics of such vast and international studies of this magnitude had simply never been done before. However, Dr Altshuler successfully pioneered the international collaborations and infrastructures that have enabled these studies to be accomplished. This achievement alone is impressive but having almost all of the various investigative teams coordinated in a science project of this size and scope had simply never been done before.
The reward for these Herculean endeavors has been a clear establishment of the genes/proteins/and now biological pathways, which when mutated underlie type 2 diabetes. Even more remarkable is the surprising fact that many of these genes and pathways do not relate primarily to insulin resistance but are β cell in origin. These startling findings imply that defects in insulin signaling and secretion are basic and early features of the pathogenesis of type 2 diabetes. His research is now focusing on their association with various responses of diabetes to treatment, diet, and exercise and are beginning to build a new pathophysiologic understanding of type 2 diabetes that has been lacking. Even more importantly, this approach has proven quite robust and now been used successfully in schizophrenia, inflammatory bowel disease, multiple sclerosis (MS), and many other common conditions that share the polygenic mode of inheritance of type 2 diabetes. Eventually, it has become clear that nearly all of these polygenic diseases will eventually fall to these approaches to identify disease-causing genes. So whereas many investigators were initially skeptical of these GWAS approaches when Dr Altshuler started, nearly everyone has now been converted to his thinking as the list of new genes continues to grow as does their coherence in defining biological pathways to attack therapeutically.
Not only has Dr Altshuler's studies been empowering to investigators everywhere in their importance and scope but they have also permitted him to assemble a team of young geneticists, endocrinologists, and bioinformaticians that will clearly populate this field for a generation. His generous mentoring and prescient scientific impact upon this growing pipeline of young clinical investigators cannot be overstated. He has proven to be a wise and caring mentor and is now a real beacon for the future of genetics in endocrinology. His impact has been and continues to be vast on our field.
William F. Crowley, Jr, MD Dr Bilezikian has served in both traditional and nontraditional mentorship roles, having influenced and furthered the careers of many in our field. He has trained more than 40 individuals, many of whom have gone on to make their own notable contributions to the field of bone and mineral research. His first Endocrinology Fellow, Dr Elizabeth Shane (Professor of Medicine at the College of Physicians and Surgeons), has followed in her mentor's footsteps in serving as President of the American Society of Bone and Mineral Research. Among the many he has trained, more than 70% have academic faculty appointments, with 9 holding positions at the professorial rank. More than 90% have faculty or leadership positions at medical schools, at the NIH, or in the pharmaceutical industry. He has also populated the field not only with investigators who have followed his own investigative themes of parathyroid disorders but also with other investigators whose careers have branched into areas as diverse as transplantation bone disease, renal bone disease, osteoporosis in premenopausal women, osteoporosis in men, osteoporosis in HIV disease, bone and mineral metabolism in African American and Chinese American women, skeletal health in diabetes mellitus, novel therapeutic regimens for osteoporosis, biochemical markers of bone remodeling, and also on the GH/ IGF-1 axis and hypothalamic/pituitary/adrenal metabolism.
The reach of Dr Bilezikian's mentorship activities extends far beyond the borders of the United States. His mentees are now sowing the seeds of his efforts in Armenia, Brazil, Australia, Argentina, China, Germany, Greece, Hong Kong, Italy, Japan, Iran, and Lebanon. His international mentorship reach in metabolic bone diseases is perhaps best illustrated by his role as a mentor in the inaugural class of an International Fellowship Program initiated 6 years ago by the Endocrine Society. Dr Barbara Silva (Belo Horizonte, Brazil), is the first recipient of this award. Her work with Dr Bilezikian culminated in 2012 in her being awarded a PhD degree. Dr Bilezikian has also had a significant impact on fellows outside Columbia University. He is Chair of the Endocrine Fellows Foundation (EFF), a nonprofit organization that over the past 20 years has provided competitive research grants to Endocrinology fellows. In addition, EFF conducts scientific forums for fellows and publishes a newsletter written for and by fellows. Dr Bilezikian's commitment to mentorship has been unwavering throughout his career. He has defined himself, most appropriately, as a teacher locally, nationally, and internationally. His passion for our field is palpable and is matched only by his boundless enthusiasm in transmitting that passion to others, irrespective of nationality, race, sex, or creed. For all the reasons cited above, there is no one more deserving of this year's Distinguished Educator Award than Dr John Bilezikian.
Luiz Henrique Griz, MD, PhD, FACE
Citation for the 2014 Distinguished Physician Award of the Endocrine Society to Dr Robert Dluhy
Bob Dluhy graduated from Princeton University magna cum laude and Phi Beta Kappa with a BA in biology and then moved to Boston for medical school and never left. After receiving his medical degree from Harvard in 1962, Bob did his internal medicine training and endocrine fellowship at the Peter Bent Brigham Hospital (now known as Brigham and Women's Hospital). Over the next 50 years, he established a remarkable career in endocrinology, achieving a stellar reputation as one of the world experts in endocrine hypertension, adrenal physiology, and adrenal diseases. Bob has written more than 100 peer-reviewed publications and more than 70 reviews, editorials, and book chapters. His research has focused primarily on endocrine hypertension and the renin-angiotensin-aldosterone axis, with studies ranging from basic laboratory-oriented research to the genetics of human hypertension. In an article published in The Journal of Clinical Investigation, Bob and colleagues were the first to show that small increases in blood potassium levels increased aldosterone independent of ACTH and the renin-angiotensin system. He also documented that potassium, chloride, and calcium, independent of sodium, regulated the secretion of renin. Taken together, these studies provided the basis for understanding the regulation of the renin-angiotensin-aldosterone system in normal human physiology.
Bob's most important research contribution to the field of endocrine hypertension was characterization of the hereditary hypertensive disorder, glucocorticoid-remediable aldosteronism (GRA). He astutely recognized that a clinic patient had a rare but heritable form of hypertension. Further studies detected a high level of circulating 18-hydroxycortisol in this patient, a finding diagnostic of GRA. With the help of Dr Richard Lifton, a young research fellow in the Division, Bob found a chimeric gene that fused the promoter region of the II β hydroxylase gene to the coding sequence of the aldosterone synthetase gene. This elegant work was published in Nature and has been heralded as a model for studying and understanding the genetics of essential hypertension. Bob received the Hoechst Marion Roussel Mentor Award from the American Heart Association for this important discovery.
In addition to his major accomplishments in research, Bob has continued a very active clinic and teaching schedule. He precepts the longitudinal fellows clinic every week and maintains a busy general endocrine office-based practice of his own. Patients come to see him from all over the world, usually with adrenal hypertension from Cushing's syndrome, pheochromocytoma, or hyperaldosteronism. He is absolutely beloved by his patients and continues to serve as both the primary care physician and endocrinologist for many of them. He also attends on the inpatient endocrine service every year and is a frequent lecturer on a wide variety of endocrine topics for the fellows, Brigham residents, Harvard Medical students, and local physicians. He provides intensive mentorship for all of the Brigham fellows and established a multidisciplinary Adrenal Center headed by a former fellow.
Bob also serves as Associate Editor at The New England Journal of Medicine (NEJM) where, for more than 13 years, he has sought and sent out for review many of the most important clinical and scientific studies in our field. His intense involvement at NEJM reflects a lifelong commitment to scholarship, excellence, and expansion of our understanding about endocrinology.
At our Endocrine Division, Bob serves as Director of the Fellowship Program and Director of the Outpatient Clinic. He is often the first to come in and the last to leave at night, working with fellows, mentoring junior faculty, calling patients, or making rounds at the hospital. In the words of a former fellow, Bob Dluhy "is the quintessential master clinician, mentor, and academic thinker . . . His influence shaped and molded my entire medical training . . .." Another faculty member stated that despite working with a number of remarkable physicians and endocrinologists, "none have made such a lasting impression on me than Bob Dluhy."
After working closely with Bob for the past 7 years, I have come to appreciate him as the consummate physician and academician. His encyclopedic knowledge about all things endocrine is legendary and remains remarkably cutting edge. He continues to learn, question dogma, and teach critical thinking and shares his insights generously by thinking out loud. With his quiet force of personality and wry sense of humor, even the most prosaic clinic or conference can be infused with magic as he explains a concept, a mechanism, or a clinical pearl. He has been an inspirational role model for generations of endocrinologists.
In summary, Bob Dluhy epitomizes the master clinician, educator, mentor, and scholar and as such is thoroughly deserving of the 2014 Distinguished Physician Award from the Endocrine Society.
Carolyn Becker, MD Citation for the 2014 Richard E. Weitzman Memorial Award of the Endocrine Society to Dr Antonio Moschetta
Born and raised in Bitonto, a small town in Southern Italy, Antonio Moschetta was the first of 3 children to his mother, a teacher, and his father, a gastroenterologist. Antonio was raised to understand the importance of knowledge and science and initiated into the fascinating world of medicine. He graduated with honors in Internal Medicine from the University of Bari in 1997 and immediately pursued a training period abroad, with the aim of developing his multidisciplinary interests ranging from gastrointestinal (GI) system pathophysiology to lipid metabolism and molecular biology. After receiving his MD, he enrolled in a PhD program in Hepatology and Gastroenterology at the University Medical Center of Utrecht in The Netherlands. In Utrecht, he had the privilege to be mentored and trained by some of the greatest experts in the field of biliary lipids including Gerard P. van Berge Henegouwen, Albert K. Groen, and Karel J. van Erpecum. His PhD thesis was on the molecular interactions between bile acids, phospholipids, and cholesterol with a focus on bile formation and bile acid toxicity. His fellowship in Hepatology and Gastroenterology at Utrecht led him to David Mangelsdorf's laboratory at University of Texas Southwestern Medical Center in Dallas, where he was recruited as a Howard Hughes Medical Institute Research Fellow. By that time the nuclear receptor field was blooming, and new discoveries were just around the corner for those, like Antonio, willing and eager to unravel unexplored molecular and biochemical frameworks and reveal new scenarios where an intestinal hormone could act directly on the liver. As a postdoctoral fellow at UT Southwestern, he published a seminal paper on the role of the bile acid nuclear receptor farnesoid X receptor (FXR) in prevention of cholesterol gallstone disease, which captured the cover of Nature Medicine. He also coauthored seminal papers exploring the function of the fibroblast growth factor 15/19, an intestine-derived hormone that regulates hepatic bile acid synthesis. At the age of 32, Antonio returned to Italy and started his own independent laboratory. He has flourished there, due to his multidisciplinary strategic view combined with skillful use of animal models and fruitful and long-lasting international collaborations. Since September 2005, Antonio's laboratory has had a major impact in the field of nuclear receptors, with a special relevance and emphasis in GI biology and pathophysiology. He has mentored 14 PhD students and 8 postdoctoral fellows and made many seminal discoveries. Using a novel transgenic mouse model, Antonio elucidated pathways by which the nuclear receptor liver X receptor (LXR) contributes to HDL cholesterol formation and cholesterol efflux, with important therapeutic implications in the treatment of atherosclerosis. Antonio identified the selective role of intestinal FXR as a central regulator of hepatic disorders, with stimulation of fibroblast growth factor 15/19 hormone expression emerging as a potential novel therapy in inflammatory and metabolic disease such as cholestasis and more recently in hepatocarcinoma. Antonio also pioneered studies on how lipid-sensing nuclear receptor and nuclear receptorcoactivator driven pathways control enterocyte lifespan and promote susceptibility to intestinal tumorigenesis.
His scientific contributions have been recognized by many invitations to present his work at leading institutions around the world and as speaker at and chairman of international conferences such as Keystone Symposia, EMBO meetings, and FALK Symposia. He has been awarded several prizes, including Young Investigator Awards from the Italian Society of Internal Medicine (2000) and Italian Society of Gastroenterology (2002) in the Japanese population was characterized by impaired insulin secretion from pancreatic β-cells, rather than the conventional view that described insulin resistance as the primary defect in Caucasians. This finding is now quite widely accepted and probably accounts for the major differences in the approach to treating diabetes in Japanese as well as Asian subjects, in whom the β-cell remains a key target of therapy. From 1977 to 1979, he conducted diabetes research under the direction of Professor Dan Porte, Jr at the University of Washington (Seattle). After returning to Japan, he joined the Faculty of Medicine as chief of a diabetes medical care and research team under the leading endocrinologist Professor Hiroo Imura in the Second Department of Internal Medicine, Kyoto University. He investigated the biological actions of various regulatory peptides including somatostatin, glucagon, pancreatic polypeptide, and glucose-dependent insulinotropic polypeptide (GIP) in diabetic and other pathological conditions. Among his many important contributions, Professor Seino elucidated the structures of the prepro GIP and GIP genes and led clinical studies on the relationships among genetic polymorphisms and diabetes and identified a novel point mutation in the human insulin gene, "proinsulin Kyoto." Professor Seino has been a leader in the biology of GIP for several decades. He generated mice with a targeted mutation of the GIP receptor gene (GIPR) and elucidated multiple novel Gipr -/-phenotypes, including the novel findings linking GIP action to the control of adipose tissue mass and body weight. These efforts have substantially contributed to the rationale for development of incretin-based therapies for the treatment of type 2 diabetes.
Professor Seino has been Executive Director of the Japan Diabetes Society since 1997 and Chairperson of the Japan Association for Diabetes Education and Care since 2005. He established the Japan Society of Metabolism and Clinical Nutrition and has been its Chairperson since 1997. Yutaka has served as Editor-in-Chief of the journal published by the Japan Diabetes Society and chief of the membership approval committee of the Japan Diabetes Society, and he has contributed significantly to the development, growth, and outreach of the Japan Association for Diabetes Education and Care. As a direct result of his encouragement and leadership, this association has grown into a large organization of 105 000 members. During the second month of his fellowship, he cared for 3 patients with adrenal masses incidentally discovered on imaging studies. At the time, the medical literature recommended that all such masses be removed. When all 3 masses proved benign, he felt we needed a better way to assess them. He published an approach in the Annals of Internal Medicine in 1983 that avoided surgery for most these masses. He has maintained an interest in this subject and later collaborated with the Massachusetts General Hospital (MGH) Department of Radiology to evaluate the utility of delayed enhanced CT scans in distinguishing primary adrenal carcinomas from adenomas.
Seeking a full-time clinical practice where he could continue a relationship with MGH, he joined a group at Salem Hospital, now North Shore Medical Center (NSMC). After 10 years there, he became Chief of the Endocrinology Division. He brought bone densitometry to NSMC, enhanced the American Diabetes Association-certified patient management program, chaired the Pharmacy and Therapeutics Committee, taught the medical residents and students, and coordinated medical resident research. In the past 5 years, the Endocrinology Division expanded from 3 endocrinologists who had been there more than 15 years to the current 6 with another starting in summer 2014. He continues to teach Endocrine Fellows at MGH on topics in diabetes and adrenal diseases. He has authored or coauthored more than 50 original research reports, case reports, chapters, and reviews.
Since 2001, Dr Copeland has channeled his interest in obesity, working part-time in the MGH Weight Center where he joined Dr Lee Kaplan. He has collaborated with the MGH Department of Psychiatry in research on obesity and metabolism in patients with schizophrenia. In 2012, he obtained the newly offered certification of the American Board of Obesity Medicine.
Dr Copeland has a long-standing interest in the communication of medical knowledge. In college, he was chairman of Yale Scientific, the undergraduate science magazine. In medical school, he was student editor of the Yale Journal of Biology and Medicine. He has been a peer reviewer for 15 journals and is an editor of the Journal of Eating Disorders. He serves on the Committee on Publications for the Massachusetts Medical Society, which oversees and advises on the activities of the Society's publications, including The New England Journal of Medicine.
He has been active with the Endocrine Society and has given meet the professor sessions on the incidentally discovered adrenal mass and presented at the inaugural Master Clinician session. As former Chair of the Continuing Medical Education Advisory Committee, Dr Copeland helped prepare the Society for Accreditation Council for Continuing Medical Education (ACCME) reaccreditation, which it received with commendation. He has also served on the Finance and Audit Committee and Nominating Committee. He has attended every ENDO since 1984 and enjoys coordinating an informal outing of baseball enthusiasts to a major league game in the host city each year. Dr Copeland's strongest concern is the care of his patients. As one patient put it, "he makes me and my situation his priority."
In the community Dr Copeland has given patient education lectures on diabetes and osteoporosis and appeared on local radio and television programs. He has long been on the Board of Directors of Cohen Hillel Academy, a K through 8 school and coached Little League baseball for 5 years. He is married to Dr Maura Copeland, a geriatric psychiatrist at MGH, and they have 3 children, Marni, a recent graduate of the University of Delaware where she was president of her sorority and the university's Greek Council, Dan, an engineering student at Vanderbilt University, and Harry, a high school junior who is captain of the varsity soccer team. Their work with COUP-TFII in angiogenesis, tumor growth, and metastasis will make a difference in the future of cancer treatments. Angiogenesis is essential for tumor growth and metastasis. COUP-TFII regulates multiple signal pathways to control angiogenesis within the tumor microenvironment. COUP-TFII expression is up-regulated in primary prostate cancers and further increased in metastatic cancers, demonstrating that COUP-TFII is an excellent prognostic marker when combined with other commonly used markers. Mice with increased expression of COUP-TFII develop tumors that metastasize to distant organs. These results show that COUP-TFII is essential for both tumor growth and metastasis. Small molecule inhibitors of COUP-TFII will probably be beneficial for cancer treatment.
They have increased the understanding of certain reproductive problems through their research of COUP-TFII. Ablation of COUP-TFII in the mouse uterus results in infertility due to defects in placentation and implantation. COUP-TFII mediates Indian hedgehog/progesterone signaling to inhibit epithelial estrogen activity, establishing the requirement for epithelia-stroma interaction during implantation. Deletion of COUP-TFII in the myometrium of the uterus results in uterine leiomyomas with 100% penetrance. These mouse models provide excellent tools for understanding the mechanisms underlying common reproductive defects.
The Tsais' COUP-TFII research also has increased an understanding of cardiovascular disease since the proteins play a vital role in vein/artery and atrium/ventricle fate. COUP-TFII is expressed in the vein but not in the artery. In endothelialspecific COUP-TFII-deficient mice, veins acquire molecular and functional characteristics of arteries, whereas ectopic expression of COUP-TFII in the arterial endothelium converts arteries to veins. Thus, COUP-TFII specifies vein/artery identity during development. COUP-TFII also specifies identity of atrial/ ventricular cardiomyocytes, albeit through different signaling pathways. Delineating COUP-TFII functions during vascular and heart development has provided insights into the underlying causes of vascular diseases, including cerebral cavernous malformation (CCM), coronary disease, and congenital heart defects. Further, elevated COUP-TFII expression has been observed in stressed hearts of patients with nonischemic cardiomyopathy and in a pressure-overloaded mouse model. Overexpression of COUP-TFII in cardiomyocytes results in heart failure with dilated cardiomyopathy. These studies raise the possibility that inhibiting COUP-TFII activity may prevent heart failure and prolong the life of patients with heart failure.
Their further COUP-TFII studies could make a substantial difference in infant mortality rates due to congenital diaphragmatic hernia (CDH). CDH with malformation of the diaphragm occurs in approximately 1 in every 2500 live births, leading to a high rate of neonatal death. Foregut mesenchyme-specific COUP-TFII-deficient mice exhibit phenotypes of CDH. As COUP-TFII deletion induces CDH and the COUP-TFII gene maps in the CDH region (15q26), COUP-TFII is a candidate gene for CDH. COUP-TFII serves as a prenatal diagnostic marker for patients with potential CDH and improves the window of therapeutic intervention.
These researchers have also shown a vital link between COUP-TFI and neuronal function. COUP-TFI is important for the specification of the cortex and for the maintenance of cortical identity. Mice without COUP-TFI show disruption in axonal path finding, demonstrating that COUP-TFI is essential for proper axonal guidance. In addition, COUP-TFI is important for oligodendrocyte differentiation and axon myelination. Thus, COUP-TFI regulates multiple roles in neuronal development.
As they drilled deeper into BETA2/NeuroD function in pancreas and neurons, the Tsais might have found the keys to an astonishing variety of ailments and disorders. BETA2/NeuroD is a versatile transcription factor important for proper differentiation of pancreatic islets and neurons. Without BETA2/NeuroD, animals develop diabetes and various behavioral defects, such as ataxia, imbalance, deafness, blindness, and limbic seizure. These defects are due to the malformation of a panel of cell types, including pancreatic islets, granule cells of the cerebellum and dentate gyrus, neurons of the VIII ganglion, inner ear hair cells, and retinal cells. This seminal work led to the discovery of BETA2/NeuroD as a maturity-onset diabetes of the young (MODY) gene and provides a model to study blindness, deafness, and seizure defects.
Finally, the Tsais' research has also made inroads in one of the biggest public health problems in developing countries today: obesity. COUP-TFII plays a role in mesenchymal stem cell fate determination. Mice with loss of one copy of COUP-TFII are leaner with smaller white adipose tissue (WAT) mass, increased thermogenesis and insulin sensitivity, and increased bone density and muscle mass. Because COUP-TFII heterozygous mice are more resistant to obesity and are more insulin sensitive, COUP-TFII is a target for drug intervention for metabolic syndromes.
As evidenced above, the ground-breaking discoveries by Drs. Ming-Jer and Sophia Tsai over the past 2 decades have elucidated not only the mechanism of action of these nuclear orphan receptors but also their roles from developmental cell fate determination to numerous human diseases. Their current work toward discovering small molecule inhibitors to target these genes can lead to therapeutic strategies for the treatment of diabetes, heart failure, cancer, and metabolic syndromes.
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